Axsome reports late-stage depression trial defeat, shares wilt
Months after reporting its experimental drug cleared a late-stage study in major depressive disorder, Axsome Therapeutics unveiled data from a pivotal study in treatment-resistant depression that showed the drug failed to meet the main goal.
In general, trials testing depression drugs are notoriously tricky and prone to failure, in major part due to high rates of the placebo effect. Existing antidepressants often take weeks to kick in, and typically work only in some patients. This trial tested the therapy in patients who had failed to benefit from two or three prior treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
